Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Lyrica Is First Drug Approved For Fibromyalgia

This article was originally published in The Pink Sheet Daily

Executive Summary

Company has said it believes indication could add $1 billion in incremental Lyrica sales.

You may also be interested in...



Pfizer Discontinues Two Phase III Primary Care Projects

Pfizer is halting development of treatments for generalized anxiety disorder and fibromyalgia.

Pfizer Discontinues Two Phase III Primary Care Projects

Pfizer is halting development of treatments for generalized anxiety disorder and fibromyalgia.

Pfizer's Pain Pipeline No Sore Spot: Firm Pursues Novel Targets, New Markets

Pfizer's investment in pain R&D is aimed at capturing two of the most significant advantages in the pharmaceutical industry: unmet medical need and innovative drug targets. With a track record in the field and over 80 percent of its pain pipeline hitting novel targets, Pfizer should be well-situated to capitalize on that opportunity.

Related Content

Topics

UsernamePublicRestriction

Register

PS066216

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel